Free Newsletter
Sanofi aims for acne vaccine in new pact
Lured by the $3 billion acne treatment market, Sanofi Pasteur has inked a collaboration deal with with the University of California, San Diego to develop an immunological approach to fighting the skin condition.
Current treatments for acne use benzoyl peroxide and oral or topical antibiotics, which the company notes can disrupt the skin's balance and lead to more resistant forms of the bacteria. The collaboration will attempt to develop a vaccine that will neutralize Propionibacterium acnes factors in inflammation. Financial details of the two-year agreement weren't disclosed.
"This opportunity could provide an immunotherapeutic product with significant benefits and a novel mechanism of action to address an unmet medical need," noted Dr. Elias Zerhouni, president of Global R&D, in a release. "This investigational vaccine and treatment may lead to a better solution for the many who suffer from this skin disease."
- here's the Sanofi release
Related Article:
Pimple treatments pocked with poor supporting science
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: